The fact sheet highlights study results on ImmunoSEB and ProbioSEB CSC3 from Specialty Enzymes & Probiotics in post-COVID subjects.
The National Institute of Health (NIH) Office of Dietary Supplements included ImmunoSEB, a blend of nine proteolytic and antioxidant enzymes, and ProbioSEB CSC3, a blend of three Bacillus species probiotics (both from Specialty Enzymes & Probiotics, based in Chino, CA), in its Fact Sheet for Health Professionals: Dietary Supplements in the Time of COVID-19. The Fact Sheet highlights study results, published in Medicines, on both ingredients in post-COVID people. It states that "After 14 days of treatment, fatigue resolved in 91% of individuals who took the enzyme and probiotic supplement and only 15% of individuals who took the placebo."
"We're proud that NIH has recognized the safety and efficacy of ImmunoSEB and ProbioSEB CSC3, especially in today's global health crisis," said Vic Rathi, founder and president of Specialty Enzymes & Probiotics, in a press release. "Our mission is to create powerful natural products to promote good health, and we've done that with this potent enzyme and probiotics combo."